Conclusion:
Research on COVID-19-related treatment can guide clinicians in their practice. This study, in addition to several others published in the literature, proves that COVID-19 monoclonal antibodies, such as Sotrovimab, are effective against COVID-19 infection when given early in the course of the disease, and may contribute to preventing mortality and complications in high-risk individuals. This study paves the way to conduct larger trials on special groups of subjects with immune-compromising conditions and, to study groups that represent the population, in order to further assess the benefit of monoclonal antibodies and identify patients who would benefit the most from their use. The availability of Sotrovimab at our hospital was made possible through a generous donation and its use generated positive outcomes. This emphasizes the need to support low-income countries so that patients around the world can benefit from the therapeutic advances made in the management of COVID-19.